The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy of Anti-Leishmania Therapy in Visceral Leishmaniasis among HIV Infected Patients: A Systematic Review with Indirect Comparison
Open accessAbstract
OBJECTIVE: We conducted a systematic literature review with indirect comparison of studies evaluating therapeutic efficacy and toxicity associated to visceral leishmaniasis (VL) therapy among HIV infected individuals. MAIN OUTCOME MEASUREMENTS: The outcomes of interest were clinical and parasitological cure, mortality, and adverse events. METHODS: PRISMA guidelines for systematic reviews and Cochrane manual were followed. Sources were MEDLINE, LILACS, EMBASE, Web of Knowledge databases and manual search of references from evaluated studies. We included all studies reporting outcomes after VL treatment, regardless of their design. Study quality was evaluated systematically by using the Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Comprehensive Meta-Analysis software v.2.2.048 was used to perform one-group meta-analysis of study arms with the same drug to estimate global rates of success and adverse events with each drug. These estimates were used, when possible, to indirectly compare treatment options, adjusted for CD4 count. Direct comparison was pooled when available. RESULTS: Seventeen studies reporting five treatment regimens and outcome of 920 VL episodes occurring in HIV infected individuals were included. The main outstanding difference in outcome among the treatment regimens was observed in mortality rate: it was around 3 times higher with high-dose antimony use (18.4%, CI 95% 13.3-25%), indirectly compared to lipid formulations of amphotericin B treatment (6.1%, CI 95% 3.9-9.4%). It was observed, also by indirect comparison, higher rates of clinical improvement in study arms using amphotericin B than in study arms using pentavalent antimonial therapy (Sb(v)). The parasitological cure, an outcome that presented some degree of risk of selection and verification bias, had rates that varied widely within the same treatment arm, with high heterogeneity, hampering any formal comparison among drugs. One direct comparison of amphotericin and antimoniate was possible combining results of two studies and confirming the superiority of amphotericin. CONCLUSIONS: Available evidence suggests that amphotericin is superior to antimony treatment. Death rate using antimoniate high dose is unacceptably high. Randomized controlled trials are necessary to compare different formulations and doses of amphotericin, alternative therapies and drug combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
Research works printed but not linked: 38
- J Alvar, 2008, The relationship between leishmaniasis and AIDS: the second 10 years, Clin Microbiol Rev, 21, 334, 10.1128/CMR.00061-07 · DOI · Paper page
- HW Murray, 2010, Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India, Future Microbiol, 5, 1301, 10.2217/fmb.10.92 · doi:10.2217/fmb.10.92
- HW Murray, 2004, Treatment of visceral leishmaniasis in 2004, Am J Trop Med Hyg, 71, 787, 10.4269/ajtmh.2004.71.787 · doi:10.4269/ajtmh.2004.71.787
- R Paredes, 2003, Leishmaniasis in HIV infection, J Postgrad Med, 49, 39, 10.4103/0022-3859.929 · DOI
- GF Cota, 2011, Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review, PLoS Negl Trop Dis, 5, e1153, 10.1371/journal.pntd.0001153 · doi:10.1371/journal.pntd.0001153
- K Ritmeijer, 2001, Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome, Trans R Soc Trop Med Hyg, 95, 668, 10.1016/S0035-9203(01)90110-5 · doi:10.1016/s0035-9203(01)90110-5
- R Paredes, 1997, Leishmaniasis in HIV-infected persons: a review, J Int Assoc Physicians AIDS Care, 3, 22
- EM Moore, 2010, Treatment of visceral leishmaniasis, J Glob Infect Dis, 2, 151
- AM Glenny, 2005, Indirect comparisons of competing interventions, Health Technol Assess, 9, 1
- G Gartlehner, 2008, Direct versus indirect comparisons: a summary of the evidence, Int J Technol Assess Health Care, 24, 170, 10.1017/S0266462308080240 · DOI
- A Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med, 6, e1000100, 10.1371/journal.pmed.1000100 · DOI · Paper page
- E Ribera, 1995, Visceral leishmaniasis in patients with HIV infection, Enferm Infecc Microbiol Clin, 13, 73
- E Ribera, 1996, Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients, Am J Med, 100, 496, 10.1016/S0002-9343(97)89503-4 · doi:10.1016/s0002-9343(97)89503-4
- F Laguna, 1997, Visceral leishmaniasis in patients infected with the human immunodeficiency virus, Eur J Clin Microbiol Infect Dis, 16, 898, 10.1007/BF01700556 · doi:10.1007/bf01700556
- C Montalban, 1990, Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS, J Infect, 21, 261, 10.1016/0163-4453(90)93933-J · doi:10.1016/0163-4453(90)93933-j
- R Russo, 1996, Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome), The Journal of infection, 32, 133, 10.1016/S0163-4453(96)91343-2 · DOI
- R Lopez-Velez, 1998, Serologic cross-reactions to Leishmania infantum using indirect immunofluorescence in HIV+ and HIV- patients with active tuberculosis, Enferm Infecc Microbiol Clin, 6, 130
- N Berhe, 1999, HIV viral load and response to antileishmanial chemotherapy in co-infected patients, AIDS, 13, 1921, 10.1097/00002030-199910010-00015 · doi:10.1097/00002030-199910010-00015
- F Laguna, 2003, Treatment of leishmaniasis in HIV-positive patients, Ann Trop Med Parasitol, 97, 135, 10.1179/000349803225002606 · DOI
- K Ritmeijer, 2006, A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection, Clin Infect Dis, 43, 357, 10.1086/505217 · doi:10.1086/505217
- I Molina, 2007, Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients, J Antimicrob Chemother, 60, 837, 10.1093/jac/dkm294 · DOI
- PK Sinha, 2011, Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India, Clin Infect Dis, 53, e91, 10.1093/cid/cir521 · doi:10.1093/cid/cir521
- K Ritmeijer, 2011, Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence, Clin Infect Dis, 53, e152, 10.1093/cid/cir674 · DOI
- F Laguna, 1999, Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group, AIDS, 13, 1063, 10.1097/00002030-199906180-00009 · doi:10.1097/00002030-199906180-00009
- J Delgado, 1999, High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients, Am J Trop Med Hyg, 61, 766, 10.4269/ajtmh.1999.61.766 · doi:10.4269/ajtmh.1999.61.766
- FM Delgado, 1997, The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection, Ann Med Interne, 14, 506
- E Rosenthal, 1995, Visceral leishmaniasis and HIV-1 co-infection in southern France, Trans R Soc Trop Med Hyg, 89, 159, 10.1016/0035-9203(95)90476-X · doi:10.1016/0035-9203(95)90476-x
- V Pintado, 2001, Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study, Medicine, 80, 54, 10.1097/00005792-200101000-00006 · doi:10.1097/00005792-200101000-00006
- V Pintado, 2001, HIV-associated visceral leishmaniasis, Clin Microbiol Infect, 7, 291, 10.1046/j.1198-743x.2001.00262.x · doi:10.1046/j.1198-743x.2001.00262.x
- M den Boer, 2006, Treatment options for visceral leishmaniasis, Expert Rev Anti Infect Ther, 4, 187, 10.1586/14787210.4.2.187 · doi:10.1586/14787210.4.2.187
- F Frezard, 2009, Pentavalent antimonials: new perspectives for old drugs, Molecules, 14, 2317, 10.3390/molecules14072317 · DOI
- SL Croft, 2002, Curr Pharm Des, Curr Pharm Des, 8, 319
- BL Herwaldt, 1992, Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies, The Am J Trop Med Hyg, 46, 296, 10.4269/ajtmh.1992.46.296 · doi:10.4269/ajtmh.1992.46.296
- J Adler-Moore, 2002, AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience, J Antimicrob Chemother, 49, 21, 10.1093/jac/49.suppl_1.21 · DOI · Paper page
- M Balasegaram, 2012, Liposomal amphotericin B as a treatment for human leishmaniasis, Expert Opin Emerg Drugs, 17, 493, 10.1517/14728214.2012.748036 · DOI · Paper page
- S Donegan, 2010, Indirect comparisons: a review of reporting and methodological quality, PloS One, 5, e11054, 10.1371/journal.pone.0011054 · DOI
- F Song, 2003, Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses, BMJ, 326, 472, 10.1136/bmj.326.7387.472 · DOI · Paper page
- F Song, 2011, Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study, BMJ, 343, d4909, 10.1136/bmj.d4909 · DOI · Paper page
Cited by
Alcohol-Related Risk of Suicidal Ideation, Suicide Attempt, and Completed Suicide: A Meta-Analysis
Darvishi, N., Farhadi, M., Haghtalab, T., & Poorolajal, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126870 · Cited by 464
Aronson, N., Herwaldt, B. L., Libman, M., Pearson, R., Lopez-Velez, R., Weina, P., Carvalho, E. M., Ephros, M., Jeronimo, S., & Magill, A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw670 · Cited by 458
Screen time and childhood overweight/obesity: A systematic review and meta‐analysis
Fang, K., Mu, M., Liu, K., & He, Y. (2019) · Child: Care, Health and Development · doi:10.1111/cch.12701 · Cited by 396
Li, T., Wei, S., Shi, Y., Pang, S., Qin, Q., Yin, J., Deng, Y., Chen, Q., Wei, S., Nie, S., et al. (2016) · British Journal of Sports Medicine · doi:10.1136/bjsports-2015-094927 · Cited by 284
Recent advances and new strategies on leishmaniasis treatment
Roatt, B. M., de Oliveira Cardoso, J. M., De Brito, R. C. F., Coura-Vital, W., de Oliveira Aguiar-Soares, R. D., & Reis, A. B. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10856-w · Cited by 253
Metadata
- Authors
- Cota, G. F., de Sousa, M. R., Fereguetti, T. O., & Rabello, A.
- Venue
- PLoS Neglected Tropical Diseases
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-02
- Volume
- 7
- Issue
- 5
- Pages
- e2195
- ISSN
- 1935-2727 (ISSN-L)
- 1935-2735
- OpenAlex
- W1983173704
- Cited by
- 189
- References
- 1
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Anti-Leishmania Therapy in Visceral Leishmaniasis among HIV Infected Patients: A Systematic Review with Indirect Comparison. https://app.cochat.ai/papers/10.1371/journal.pntd.0002195
- The paper
- Cota, G. F., de Sousa, M. R., Fereguetti, T. O., & Rabello, A. (2013). Efficacy of Anti-Leishmania Therapy in Visceral Leishmaniasis among HIV Infected Patients: A Systematic Review with Indirect Comparison. PLoS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0002195
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.